{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T02:09:05Z","timestamp":1721268545543},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T00:00:00Z","timestamp":1499644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T00:00:00Z","timestamp":1499644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1038\/leu.2017.235","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T06:41:10Z","timestamp":1500878470000},"page":"2264-2267","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib"],"prefix":"10.1038","volume":"31","author":[{"given":"S","family":"Sopper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B T","family":"Gjertsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J J W M","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,10]]},"reference":[{"key":"BFleu2017235_CR1","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boque C et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014; 123: 494\u2013500.","journal-title":"Blood"},{"key":"BFleu2017235_CR2","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197\u20132203.","journal-title":"Leukemia"},{"key":"BFleu2017235_CR3","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","volume":"129","author":"A Hughes","year":"2017","unstructured":"Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood 2017; 129: 1166\u20131176.","journal-title":"Blood"},{"key":"BFleu2017235_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1200\/JCO.2016.67.0893","volume":"35","author":"S Sopper","year":"2017","unstructured":"Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A et al. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. J Clin Oncol 2017; 35: 175\u2013184.","journal-title":"J Clin Oncol"},{"key":"BFleu2017235_CR5","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1182\/blood-2015-07-655589","volume":"126","author":"DT Yeung","year":"2015","unstructured":"Yeung DT, Tang C, Vidovic L, White DL, Branford S, Hughes TP et al. KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib\/nilotinib strategy. Blood 2015; 126: 2720\u20132723.","journal-title":"Blood"},{"key":"BFleu2017235_CR6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/leu.2017.9","volume":"31","author":"C Schutz","year":"2017","unstructured":"Schutz C, Inselmann S, Sausslele S, Dietz CT, Mu Ller MC, Eigendorff E et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia 2017; 31: 829\u2013836.","journal-title":"Leukemia"},{"key":"BFleu2017235_CR7","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"M Ilander","year":"2017","unstructured":"Ilander M, Olsson-Stromberg U, Schlums H, Guilhot J, Bruck O, Lahteenmaki H et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 2017; 31: 1108\u20131116.","journal-title":"Leukemia"},{"key":"BFleu2017235_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/leu.2015.270","volume":"30","author":"A Hochhaus","year":"2015","unstructured":"Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P, Ossenkoppele G et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia 2015; 30: 57\u201364.","journal-title":"Leukemia"},{"key":"BFleu2017235_CR9","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","volume":"75","author":"K Schonberg","year":"2015","unstructured":"Schonberg K, Rudolph J, Vonnahme M, Parampalli Yajnanarayana S, Cornez I, Hejazi M et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res 2015; 75: 2187\u20132199.","journal-title":"Cancer Res"},{"key":"BFleu2017235_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12185-013-1483-9","volume":"99","author":"T Kumagai","year":"2014","unstructured":"Kumagai T, Matsuki E, Inokuchi K, Ohashi K, Shinagawa A, Takeuchi J et al. Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. Int J Hematol 2014; 99: 41\u201352.","journal-title":"Int J Hematol"},{"key":"BFleu2017235_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/leu.2011.239","volume":"26","author":"CI Chen","year":"2012","unstructured":"Chen CI, Koschmieder S, Kerstiens L, Schemionek M, Altvater B, Pscherer S et al. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia 2012; 26: 465\u2013474.","journal-title":"Leukemia"},{"key":"BFleu2017235_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.4049\/jimmunol.168.2.643","volume":"168","author":"H Nakajima","year":"2002","unstructured":"Nakajima H, Zhao R, Lund TC, Ward J, Dolan M, Hirsch B et al. The BCR\/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients. J Immunol 2002; 168: 643\u2013650.","journal-title":"J Immunol"},{"key":"BFleu2017235_CR13","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1182\/blood.V92.12.4758","volume":"92","author":"N Takahashi","year":"1998","unstructured":"Takahashi N, Miura I, Saitoh K, Miura AB . Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood 1998; 92: 4758\u20134763.","journal-title":"Blood"},{"key":"BFleu2017235_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1046\/j.1365-2141.2000.02341.x","volume":"111","author":"EK Cho","year":"2000","unstructured":"Cho EK, Heo DS, Seol JG, Seo EJ, Chi HS, Kim ES et al. Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia. Br J Haematol 2000; 111: 216\u2013222.","journal-title":"Br J Haematol"},{"key":"BFleu2017235_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000039748","volume":"104","author":"CK Min","year":"2000","unstructured":"Min CK, Yang IH, Kim DW, Lee JW, Han CW, Min WS et al. Detection of the BCR-ABL fusion gene in natural killer cells in patients with chronic myelogenous leukemia. Acta Haematol 2000; 104: 135\u2013138.","journal-title":"Acta Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2017235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2017235","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu2017235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T17:31:54Z","timestamp":1648747914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["BFleu2017235"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.235","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,10]]},"assertion":[{"value":"10 July 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors received research support from Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}